Subscribe

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer

REDWOOD CITY, Calif., May 8, 2024 — Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the...

New Survey of U.S. Oncologists Reveals Where More Work Can Be Done to Research Treatments for Advanced Non-Small Cell Lung Cancer

Survey examined oncologists’ perspective on treatment options and priorities, comorbidities and other clinical characteristics of patients with...

CRI CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey on Immunotherapy and Her Tenure

NEW YORK – Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute...

Cancer Research Institute Joins Lance Kawaguchi, #SouthPoleTrek4Cancer to Ring the Nasdaq Stock Market Closing Bell

Contact: Melinda Koski, SouthPoleTrek4Cancer Sharon Slade, Chief Marketing Officer, CRI For Immediate Release Tuesday, December 19, 2023...

The Cancer Research Institute’s Patient Immunotherapy Summit is Now Available On Demand

NEW YORK — The Cancer Research Institute (CRI) is excited to announce the premiere of the seventh...

CRI CEO Dr. Jill O’Donnell-Tormey on How Data Drives Immunotherapy Advances

New York, November 22, 2023 Recently, the Cancer Research Institute’s (CRI) CEO and Director of Scientific Affairs...

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.